Stay updated on KX2-361 Safety & PK in Refractory Malignancies Clinical Trial
Sign up to get notified when there's something new on the KX2-361 Safety & PK in Refractory Malignancies Clinical Trial page.

Latest updates to the KX2-361 Safety & PK in Refractory Malignancies Clinical Trial page
- Check6 days agoChange DetectedRevision: v3.6.6 is now displayed in place of Revision: v3.6.5, indicating a minor platform update. No study data or user-facing content is modified.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe website version was updated from v3.6.4 to v3.6.5, reflecting a maintenance release. This update does not alter the study details or visible content on the page.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4, indicating a small internal version bump. No visible content or functionality changes are introduced.SummaryDifference0.1%

- Check64 days agoChange DetectedPage revision label updated from v3.6.2 to v3.6.3, indicating a minor maintenance update to the page. This change does not alter the study details, eligibility criteria, or other content presented on the page.SummaryDifference0.1%

- Check71 days agoChange DetectedThe site software revision was updated from v3.6.0 to v3.6.2, indicating a platform update. This change does not alter the displayed study details or user-facing content.SummaryDifference0.1%

- Check85 days agoChange DetectedRecruitment status updated to no longer look for participants, indicating enrollment is closed, and new sections How to Read a Study Record, Common Questions, and How to Join a Study were added to guide users, while the Intervention/Treatment label formatting and revision version notes were updated (v3.6.0 replacing v3.5.5).SummaryDifference0.5%

Stay in the know with updates to KX2-361 Safety & PK in Refractory Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the KX2-361 Safety & PK in Refractory Malignancies Clinical Trial page.